| Literature DB >> 34325728 |
Fulvia Pimpinelli1, Francesco Marchesi2, Giulia Piaggio3, Diana Giannarelli4, Elena Papa5, Paolo Falcucci5, Antonio Spadea5, Martina Pontone1, Simona Di Martino6, Valentina Laquintana6, Antonia La Malfa7, Enea Gino Di Domenico1, Ornella Di Bella8, Gianluca Falzone5, Fabrizio Ensoli1, Branka Vujovic8, Aldo Morrone9, Gennaro Ciliberto10, Andrea Mengarelli5.
Abstract
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (p = 0.076), though large prospective study is needed to address this issue.Entities:
Keywords: COVID-19; Ph negative myeloproliferative neoplasms; mRNA vaccine
Year: 2021 PMID： 34325728 DOI： 10.1186/s13045-021-01130-1
Source DB: PubMed Journal: J Hematol Oncol ISSN： 1756-8722 Impact factor: 17.388